DATA GRAPHICS | Data Byte
Status of the CD47/SIRPA clinical pipeline
The list of clinical candidates grows as biopharma steps up to overcome hematologic toxicities
June 15, 2023 12:46 AM UTC
The hematologic toxicities of first-generation antibodies against CD47 have not deterred the field. Companies have started clinical testing of at least 33 programs, up from 10 clinical programs in 2019, with many of the new entrants aiming for improved safety via greater selectivity, or improved efficacy via addition of a second therapeutic mechanism.
Blocking of the CD47/SIRPA pathway, by which cancers send a “don’t eat me” signal to the immune system, can lead to increased macrophage-mediated phagocytosis of tumor cells. However, studies have shown that non-selective inhibition of CD47, which is also expressed on red blood cells and platelets, can cause anemia and thrombocytopenia, among other hematological toxicities. ...